Answers are grounded in this paper and cite their sources.
Discusses the economic implications of expanded CMS reimbursement guidelines for prophylactic ICD implantation.
On September 28, 2004, the Centers for Medicare and Medicaid Services (CMS) proposed new reimbursement guidelines for implantable cardioverter–defibrillators (ICDs) used for the prevention of sudden death from cardiac causes. The new guidelines dramatically increase the number of patients for whom prophylactic implantation of an ICD would be covered by Medicare. Among other things, the CMS dispensed with the controversial “QRS restriction” on patients like those who participated in the second Multicenter Automatic Defibrillator Implantation Trial — so-called MADIT-II patients. In this trial, which was reported in the Journal in 2002, ICD therapy conferred a striking survival benefit as compared . . .
No takes yet. Share an insight, caveat, or question.
Jauhar et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: